January 13, 2015 — Ambry Genetics announces the launch of cardiovascular genetic testing panels for inherited cardiomyopathies and arrhythmias. These feature an intuitive, tiered approach to testing for hypertrophic cardiomyopathy, long QT syndrome and Brugada syndrome. Sudden death may be the first and only symptom of some of these disorders. Genetic testing can be life-saving and directly impacts medical care when confirming a diagnosis and/or identifying at-risk individuals. These new panels feature next-generation sequencing, deletion/duplication analysis, comprehensive coverage and turnaround times as low as 3-4 weeks.
As with all of Ambry’s tests, cardiovascular genetic test reports will provide in-depth interpretation. An extensive literature review and assessment of all databases are performed when interpreting a gene mutation or variant of unknown significance (VUS).
The new testing includes an 84-gene comprehensive cardiovascular genetics panel (CardioNext), hypertrophic cardiomyopathy panels (HCMFirst and HCMNext), inherited arrhythmia panels (RhythmFirst and RhythmNext) and a comprehensive inherited cardiomyopathy panel (CMNext). Multi-gene panels targeted to specific inherited cardiomyopathies and arrhythmias are also available.
For more information: www.ambrygen.com
August 15, 2024 
